• NAVIN CHANDRA PANT Department of Pharmaceutical Sciences, Bhimtal Campus, Kumaun University, Nainital
  • VIJAY JUYAL Department of Pharmaceutical Sciences, Bhimtal Campus, Kumaun University, Nainital




Nanoparticles, Drug delivery, Raloxifene, Solid-lipid nanoparticles, Box-Behnken design


Objective:  The poor water solubility of the drug presents a great challenge for the formulation development and results in low oral bioavailability. The oral bioavailability of Raloxifene HCl (RLX) is very low (<2%) in humans due to its poor solubility. The objective of the present study was to develop RLX loaded solid-liquid nanoparticles for effective drug delivery.

Methods: Compritol 888 ATO-based RLX-loaded solid lipid nanoparticles (SLNs) were formulated using the oil in water microemulsion method. Drug-excipients compatibility was confirmed through Fourier transform infrared spectroscopy, Differential scanning calorimetry methods. The SLN was characterized for particle size, surface morphology, entrapment efficiency.

Results: A total of seventeen formulations (SLN1-SLN17) were developed as per the 3 levels 3 factor Box–Behnken design. The model used for the analysis was statistically analyzed using ANOVA and the goodness of fit was evaluated using diagnostic plots. As per the response-surface plots, the amount of lipid, poloxamer 407, and ultrasonication time have a significant effect on the particle size and entrapment efficiency (%EE). The developed RLX-loaded SLNs have the size and %EE in the range of 165.63±2.62 nm to 315.33±4.87 nm and 75.21±2.32% to 95.32±2.11%. The TEM analysis showed that the developed RLX-loaded SLNs were almost spherical and has a small size range.

Conclusion: The high biocompatibility, biodegradability, ability to protect drugs in GIT, and sustained release properties make SLNs an ideal candidate to resolve poor oral bioavailability challenges.


Download data is not yet available.


Moen MD, Keating GM. Raloxifene: a review of its use in the prevention of invasive breast cancer. Drugs 2008;68:2059-83.

Jose R, Eduardo C, Maria R, Emilio C, Angel A. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J 2009;3:14–21.

Hochner Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 1999;85:23–9.

Jha RK, Tiwari S, Mishra B. Bioadhesive microspheres for bioavailability enhancement of raloxifene hydrochloride: formulation and pharmacokinetic evaluation. AAPS PharmSciTech 2011;12:650–7.

Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011;12:62–76.

Remya PN, Damodharan N. Formulation, development, and characterisation of cilnidipine loaded solid lipid nanoparticles. Asian J Pharm Clin Res 2018;11:120-5.

Sharma M, Sharma R, Jain DK. Nanotechnology-based approaches for enhancing oral bioavailability of poorly water-soluble antihypertensive drugs. Scientifica 2016;8525679. DOI:10.1155/2016/8525679

Ghasemiyeh P, Mohammadi Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci 2018;13:288-303.

Sharma A, Mehta V, Parashar A, Patrwal R, Malairaman U. Solid lipid nanoparticle: fabricated through nanoprecipitation and their physicochemical characterization. Int J Pharm Pharm Sci 2016;10:144-8.

Burra M, Jukanti R, Janga K, Sunkavalli S, Velpula A, S Ampati, et al. Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. Adv Powder Technol 2013;24:393–402.

Muller R, Ruhl D, Runge S. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 1996;144:115–21.

Göppert T, Muller R. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 2005;302:172–86.

Castelli F, Puglia C, Sarpietro M, Rizza L, Bonina F. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm 2005;304:231–8.

Hao J, Fang X, Zhou Y, Wang J, Guo F. Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a box-behnken design. Int J Nanomed 2011;6:683‐92.

Wang F, Chen L, Jiang S, Jin Peng, Qunwei Xu. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using box-behnken design. J Liposome Res 2014;24:171‐81.

Gupta B, Poudel BK, Pathak S, Tak WJ, Lee HH. Effect of formulation variables on the particle size and drug encapsulation of imatinib-loaded solid-liquid nanoparticles. AAPS PharmSciTech 2016:17:652-62.

Prozorov T, Prozorov R, Suslick KS. High-velocity interparticle collisions driven by ultrasound. J Am Chem Soc 2004;126:13890–1.

Shah M, Pathak K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2 3 full-factorial design. AAPS PharmSciTech 2010;78:1–8.

Yang Y, Chung T, Bai X, Chan W. Effect of preparation conditions on morphology and release profiles of biodegradable polymeric microspheres containing protein fabricated by the double-emulsion method. Chem Eng Sci 2000;55:2223–6.



How to Cite

PANT, N. C., & JUYAL, V. (2021). FABRICATION AND CHARACTERIZATION OF RALOXIFENE LOADED SOLID-LIPID NANOPARTICLES. International Journal of Applied Pharmaceutics, 13(4), 185–191. https://doi.org/10.22159/ijap.2021v13i4.41774



Original Article(s)